Is there literature supporting the off‑label use of brexpiprazole as an adjunctive treatment for post‑traumatic stress disorder in a patient already taking lithium, fluoxetine (a strong CYP2D6 inhibitor), and bupropion extended‑release?

Off-Label Use of Brexpiprazole as Adjunctive Treatment for PTSD

There is now strong evidence supporting the off-label use of brexpiprazole as adjunctive treatment for PTSD, particularly when combined with an SSRI like fluoxetine. A 2024 phase 3 randomized clinical trial demonstrated that brexpiprazole (2-3 mg/day) combined with sertraline significantly improved PTSD symptoms compared to sertraline alone 1.

Evidence Supporting Adjunctive Brexpiprazole for PTSD

Clinical Trial Data

The most compelling evidence comes from a large, well-designed study that enrolled 416 adult outpatients with PTSD 1. Brexpiprazole + sertraline demonstrated statistically significant greater improvement in CAPS-5 total scores (the gold standard for measuring PTSD severity) compared to sertraline + placebo, with a mean difference of -5.59 points (95% CI: -8.79 to -2.38; P < .001) at week 10. All secondary efficacy endpoints were also met.

The treatment was generally well-tolerated, with common side effects including:

• Nausea (12.2% vs 11.7% placebo)
• Fatigue (6.8% vs 4.1%)
• Weight increase (5.9% vs 1.5%)
• Somnolence (5.4% vs 2.6%)

Notably, discontinuation rates due to adverse events were actually lower in the brexpiprazole group (3.9%) compared to sertraline alone (10.2%) 1.

Mechanism and Preclinical Support

Brexpiprazole's efficacy in PTSD appears related to its unique pharmacological profile as a partial D2/5-HT1A agonist with 5-HT2A and α1B/2C-adrenoceptor antagonist properties 2. Preclinical studies show that brexpiprazole blocks PTSD-like memory formation while promoting normal fear memory, and normalizes alterations in the hippocampal-amygdalar network 3. Animal studies demonstrate that adjunctive brexpiprazole with escitalopram increases hypothalamic NPY (neuropeptide Y) immunoreactivity, which may mediate stress response attenuation 2.

Additional Clinical Evidence

Beyond the phase 3 trial, case reports describe significant improvement in treatment-resistant complex PTSD in domestic violence victims when brexpiprazole was added to existing regimens 4. These patients showed enhanced response to trauma therapy with adjunctive brexpiprazole treatment.

Critical Drug Interaction Considerations in Your Patient

Your patient's medication regimen requires careful attention to dosing adjustments. The patient is taking fluoxetine, which is a strong CYP2D6 inhibitor 5. This is actually advantageous in this specific context.

Important FDA Labeling Information

The brexpiprazole FDA label explicitly states: "In the clinical studies examining the adjunctive use of brexpiprazole in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD" 5.

This means:

• Standard dosing of brexpiprazole (starting 0.5-1 mg, target 2-3 mg daily) can be used without adjustment despite fluoxetine co-administration
• The clinical trials that established efficacy in MDD included patients on fluoxetine without dose reduction
• Bupropion extended-release has no clinically significant interaction with brexpiprazole 5
• Lithium is not mentioned as having interactions with brexpiprazole

Dosing Algorithm for Your Patient

1. Start brexpiprazole 0.5 mg once daily for Week 1
2. Increase to 1 mg once daily at Week 2
3. Increase to 2 mg once daily at Week 3 (this was the lower effective dose in the PTSD trial)
4. Consider increasing to 3 mg once daily if inadequate response after 4-6 weeks at 2 mg (this was also effective in the PTSD trial) 1

No dose adjustment is needed for the fluoxetine interaction in this adjunctive treatment context 5.

Guideline Context and Limitations

Current PTSD Treatment Guidelines

The 2024 VA/DoD Clinical Practice Guideline for PTSD strongly recommends specific manualized psychotherapies (prolonged exposure, cognitive processing therapy, or EMDR) over pharmacotherapy 6. When pharmacotherapy is used, the guideline recommends paroxetine, sertraline, or venlafaxine as first-line agents 6. The guideline strongly recommends against benzodiazepines, cannabis, or cannabis-derived products 6.

Older WHO guidelines (2011) recommend graded self-exposure based on CBT principles for adults with PTSD symptoms, emphasizing psychological interventions over pharmacological approaches 7. A 2010 consensus guideline noted limited evidence for pharmacological agents in early PTSD treatment, with medication recommended as second-line therapy 8.

Important Caveat About Generalizability

A 2025 critical analysis of the brexpiprazole-sertraline PTSD trials raises an important concern: nearly 95% of patients in a real-world PTSD clinic would not have qualified for the clinical trials due to exclusion criteria 9. The most common exclusions were:

• Current major depressive disorder
• PTSD onset before age 16
• Interval between PTSD onset and current age ≥10 years

This means the evidence, while strong, may not fully represent the effectiveness in typical clinical practice populations 9. However, this limitation applies to most PTSD pharmacotherapy trials, not just brexpiprazole studies.

Clinical Decision Framework

Given the strong phase 3 evidence, brexpiprazole represents a reasonable adjunctive option for PTSD, particularly when:

• First-line SSRI monotherapy (like fluoxetine) has provided inadequate response
• The patient cannot access or has not responded adequately to trauma-focused psychotherapy
• The patient does not have contraindications to atypical antipsychotics

The combination of fluoxetine (already prescribed) with brexpiprazole mirrors the sertraline-brexpiprazole combination studied in the phase 3 trial, as both are SSRIs with similar mechanisms. The existing fluoxetine actually simplifies dosing since no adjustment is needed for the CYP2D6 inhibition 5.

Monitoring Parameters

• PTSD symptom severity using validated scales (CAPS-5 or PCL-5) at baseline and every 2-4 weeks
• Weight and metabolic parameters (baseline, then monthly for first 3 months)
• Movement disorders (akathisia, extrapyramidal symptoms)
• Mood symptoms given comorbid mood stabilizer (lithium) use
• Treatment response timeline: Expect to see improvement by 6-10 weeks based on trial data 1

The evidence base for brexpiprazole in PTSD is stronger and more recent than for many other off-label augmentation strategies, making it a defensible clinical choice when first-line treatments have been inadequate.